Insmed, Inc. (INSM)
121.90
+3.36
(+2.83%)
USD |
NASDAQ |
Aug 31, 16:00
122.10
+0.20
(+0.17%)
After-Hours: 20:00
Insmed Cash from Operations (TTM) : -778.92M for June 30, 2026
Cash from Operations (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | -778.92M |
| March 31, 2026 | -895.66M |
| December 31, 2025 | -935.01M |
| September 30, 2025 | -883.40M |
| June 30, 2025 | -844.55M |
| March 31, 2025 | -761.94M |
| December 31, 2024 | -683.88M |
| September 30, 2024 | -617.50M |
| June 30, 2024 | -572.92M |
| March 31, 2024 | -572.76M |
| December 31, 2023 | -536.25M |
| September 30, 2023 | -509.80M |
| June 30, 2023 | -463.29M |
| March 31, 2023 | -442.80M |
| December 31, 2022 | -400.44M |
| September 30, 2022 | -381.42M |
| June 30, 2022 | -367.04M |
| March 31, 2022 | -340.18M |
| December 31, 2021 | -363.30M |
| September 30, 2021 | -345.96M |
| June 30, 2021 | -329.18M |
| March 31, 2021 | -289.69M |
| December 31, 2020 | -219.35M |
| September 30, 2020 | -196.96M |
| June 30, 2020 | -190.66M |
| Date | Value |
|---|---|
| March 31, 2020 | -234.74M |
| December 31, 2019 | -250.65M |
| September 30, 2019 | -275.78M |
| June 30, 2019 | -288.90M |
| March 31, 2019 | -263.78M |
| December 31, 2018 | -257.98M |
| September 30, 2018 | -236.66M |
| June 30, 2018 | -209.41M |
| March 31, 2018 | -190.74M |
| December 31, 2017 | -159.62M |
| September 30, 2017 | -169.36M |
| June 30, 2017 | -162.10M |
| March 31, 2017 | -154.09M |
| December 31, 2016 | -146.71M |
| September 30, 2016 | -116.29M |
| June 30, 2016 | -109.34M |
| March 31, 2016 | -105.34M |
| December 31, 2015 | -100.70M |
| September 30, 2015 | -86.08M |
| June 30, 2015 | -82.96M |
| March 31, 2015 | -76.65M |
| December 31, 2014 | -64.42M |
| September 30, 2014 | -65.54M |
| June 30, 2014 | -60.92M |
| March 31, 2014 | -48.10M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 160.32M |
| Alnylam Pharmaceuticals, Inc. | 885.89M |
| Biogen, Inc. | 2.879B |
| Gilead Sciences, Inc. | 13.55B |
| Agios Pharmaceuticals, Inc. | -360.60M |